COMMUNIQUÉS West-GlobeNewswire

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
08/02/2024
Biodexa Pharmaceuticals PLC Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients CARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“ [...]
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
08/02/2024
Company’s International Reach Expanding with Latest Regulatory Approval HOUSTON, TEXAS, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that [...]
Trinity Biotech to Present at Emerging Growth Conference
08/02/2024
DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024. The [...]
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
08/02/2024
CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address [...]
Solera Announces Leadership Transition
08/02/2024
CEO Mary Langowski to Assume Role of Chairman of the Board PHOENIX, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Solera Health , the premier technology platform for connecting people seamlessly and easily to health solutions that [...]
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
08/02/2024
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health System Florian Rieder, MD, Associate Staff in [...]
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results
08/02/2024
Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023. Reports [...]
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
08/02/2024
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) [...]
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
08/02/2024
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to [...]
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08/02/2024
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing [...]
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
08/02/2024
Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability of response Centrally reviewed 12-month primary analysis data [...]
Health Catalyst to Announce Fourth Quarter and Full Year 2023 Operating Results and Host Conference Call on Thursday, February 22, 2024
08/02/2024
SALT LAKE CITY, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its [...]
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
08/02/2024
The financing, co-led by Viking Global Investors and Cormorant Asset Management with participation from The Column Group along with additional new and existing investors, follows promising early clinical data from NRTX- [...]
Tenaya Therapeutics Announces Pricing of Underwritten Offering
08/02/2024
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
08/02/2024
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME) [...]
Healthwise Ranked #1 in Patient Education in 2024 Best in KLAS Report
08/02/2024
BOISE, Idaho, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Healthwise, a leader in evidence-based health education, technology, and services, has been ranked No. 1 in Patient Education by KLAS Research in the 2024 Best in KLAS [...]
Mineralys Therapeutics Announces $120 Million Private Placement Financing
08/02/2024
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD [...]
Assembly Biosciences Announces Effective Date of Reverse Stock Split
08/02/2024
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a [...]
Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform
08/02/2024
AUTX-703 has demonstrated potent growth inhibition in preclinical models of solid tumors and a hematological malignancy An overview of the Company’s AURIGIN platform to be presented at the American Association for [...]

Pages